Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Adaptive Biotechnologies Corporation (ADPT : NSDQ)
 
 • Company Description   
Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.

Number of Employees: 858

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.71 Daily Weekly Monthly
20 Day Moving Average: 1,821,616 shares
Shares Outstanding: 142.23 (millions)
Market Capitalization: $1,096.58 (millions)
Beta: 1.08
52 Week High: $43.40
52 Week Low: $6.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.01% -8.04%
12 Week -45.93% -39.24%
Year To Date -72.52% -66.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1165 EASTLAKE AVENUE EAST SUITE 200
-
SEATTLE,WA 98109
USA
ph: 206-659-0067
fax: 206-659-0667
investors@adaptivebiotech.com http://www.adaptivebiotech.com
 
 • General Corporate Information   
Officers
Chad Robins - Chief Executive Officer; Chairman and Director
Mark Adams - Chief Operating Officer
Chad Cohen - Chief Financial Officer
Kevin Conroy - Director
Michelle Griffin - Director

Peer Information
Adaptive Biotechnologies Corporation (CORR.)
Adaptive Biotechnologies Corporation (RSPI)
Adaptive Biotechnologies Corporation (CGXP)
Adaptive Biotechnologies Corporation (BGEN)
Adaptive Biotechnologies Corporation (GTBP)
Adaptive Biotechnologies Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00650F109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 142.23
Most Recent Split Date: (:1)
Beta: 1.08
Market Capitalization: $1,096.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.67 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 2.66% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.98
Price/Cash Flow: -
Price / Sales: 7.10
EPS Growth
vs. Year Ago Period: -51.72%
vs. Previous Quarter: -2.33%
Sales Growth
vs. Year Ago Period: 0.46%
vs. Previous Quarter: 1.82%
ROE
03/31/22 - -36.67
12/31/21 - -31.00
09/30/21 - -27.07
ROA
03/31/22 - -24.10
12/31/21 - -20.62
09/30/21 - -18.07
Current Ratio
03/31/22 - 3.64
12/31/21 - 3.54
09/30/21 - 3.82
Quick Ratio
03/31/22 - 3.46
12/31/21 - 3.37
09/30/21 - 3.67
Operating Margin
03/31/22 - -148.44
12/31/21 - -134.30
09/30/21 - -129.89
Net Margin
03/31/22 - -148.44
12/31/21 - -134.30
09/30/21 - -129.89
Pre-Tax Margin
03/31/22 - -148.49
12/31/21 - -134.31
09/30/21 - -129.19
Book Value
03/31/22 - 3.89
12/31/21 - 4.28
09/30/21 - 4.62
Inventory Turnover
03/31/22 - 2.72
12/31/21 - 2.68
09/30/21 - 2.41
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©